EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study

Kuniko Sunami iD, Masashi Mikami iD, Masayuki Tanaka, Sona-Sanae Aoyagi, Kanae Togo

Cancer Science · 03.11.2026

DOI: 10.1111/cas.70561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 03.11.2026. Verfasst von Kuniko Sunami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Japan Inc, Pfizer Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Comprehensive genomic profiling (CGP) is standard for advanced solid tumors. Evidence reporting its real‐world utilization pattern and time course for guided therapy is limited. This retrospective study in Japan assessed the real‐world utility of CGP tests for advanced or metastatic solid tumors using data from the C‐CAT registry from June 1, 2019, to August 23, 2025. We evaluated the proportion of patients who received genomically matched therapy with expert panel (EP) recommendation and their overall survival (OS) compared with patients who did not receive genomically matched therapy. The study population comprised 89,552 patients who underwent CGP: median age 64.0 (interquartile range: 54.0–72.0) years, with pancreatic cancer (13,827; 15.4%) and colorectal cancer (11,322; 12.6%) the most common tumor types. System‐generated matched treatment options presented as reference information during EP review were identified in 80,185, of whom 77,337 (96.4%) received EP review, 37,245 (46.4%) were offered new therapeutic recommendations, and 7124 (8.9%) initiated EP‐recommended therapies. Among 2049 patients who were newly identified with companion diagnostic (CDx)‐related druggable alterations, 319 (15.6%) received matched therapies. Patients receiving matched therapies experienced longer OS compared with others in the overall cohort (median: 538 days vs. 356 days) and across cancer types. OS varied by the final treatment line before CGP testing, with earlier lines associated with longer survival in biliary tract, ovarian, pancreatic, and thyroid cancers. These findings highlight the need for timely CGP implementation to maximize the impact of precision oncology. Trial Registration: Japan Registry of Clinical Trials identifier: jRCT1030250365

Schlagwörter

Stichwörter der Autor:innen

C‐CATJapancomprehensive genomic profilingmolecular targeted therapyprecision oncology

Autor:innen und Institutionen

  • Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
  • Real World Evidence, Japan Access & Value, Pfizer Japan Inc., Tokyo, Japan.
  • ONC Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.

ORCID-Profile: Kuniko Sunami, Masashi Mikami

Förderung

  • Pfizer Japan Inc
  • Pfizer Japan

Zitieren

APA

Sunami, K., Mikami, M., Tanaka, M., Aoyagi, S. S., & Togo, K. (2026). Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study. Cancer Science. https://doi.org/10.1111/cas.70561

Vancouver

Sunami K, Mikami M, Tanaka M, Aoyagi SS, Togo K. Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study. Cancer Science. 2026. doi:10.1111/cas.70561

BibTeX
@article{Sunami2026,
  author = {Sunami, Kuniko and Mikami, Masashi and Tanaka, Masayuki and Aoyagi, Sona-Sanae and Togo, Kanae},
  title = {Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70561}
}
Kostenlos starten →